JAZZ
Jazz Pharmaceuticals PLC
238.00$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 30.4% | 37.4% | 15.6% | 18.9% | 23.7% | 29.4% | 43.4% | 21.2% | 24.1% | 30.2% | 38.5% | 35.7% | |
| 20.5% | 29.4% | 7.6% | 7.5% | 6.0% | 11.5% | 16.2% | 4.8% | 8.1% | 13.2% | 20.1% | 11.9% | |
| 20.5% | 29.4% | 8.9% | 11.7% | 15.8% | 19.5% | 32.6% | 4.8% | 8.1% | 14.3% | 24.9% | 20.9% | |
| 5.6% | 6.2% | 4.9% | 4.4% | 5.1% | 6.4% | 6.1% | 4.6% | 6.0% | 6.2% | 6.0% | 7.1% | |
| 0.9% | 0.6% | 0.7% | 0.8% | 1.0% | 1.4% | 1.5% | 8.7% | 6.6% | 5.2% | 4.0% | 3.6% | |
| 1.7% | 2.5% | 2.2% | 3.3% | 3.9% | 4.9% | 2.0% | 2.8% | 2.8% | – | – | – | |
| 21.0% | 19.6% | 18.6% | 18.5% | 17.8% | 16.6% | 14.7% | 14.9% | 15.6% | 15.4% | 14.3% | 15.7% | |
| 43.1% | 35.3% | 62.7% | 58.1% | 52.5% | 44.1% | 33.6% | 58.2% | 53.5% | 47.6% | 39.6% | 38.0% | |
| 58.9% | 52.4% | 60.9% | 47.0% | 47.0% | 43.8% | 44.0% | 67.8% | 71.5% | 67.2% | 65.9% | 63.0% | |
| 6.5% | 6.7% | 5.4% | 5.7% | 6.6% | 6.6% | 10.0% | 6.6% | 8.6% | 13.5% | 8.6% | 19.2% | |
| 0.3% | 1.1% | 0.8% | 0.8% | 0.6% | 0.8% | 4.0% | 0.4% | 0.4% | 5.5% | 0.4% | 9.0% | |
| 0.8% | 0.6% | 0.5% | 0.5% | 0.8% | 0.9% | 0.4% | 0.8% | 0.8% | 0.9% | 0.6% | 1.0% | |
| 39.9% | 34.7% | 41.5% | 30.1% | 30.0% | 28.4% | 28.3% | 48.9% | 52.5% | 44.8% | 50.6% | 37.1% | |
| 41.1% | 47.6% | 39.1% | 53.0% | 53.0% | 56.2% | 56.0% | 32.2% | 28.5% | 32.8% | 34.1% | 37.0% | |
| 1.0% | 9.0% | 11.0% | 17.9% | 16.2% | 19.3% | 17.7% | 6.8% | 6.8% | 7.7% | 9.4% | 5.5% | |
| 1.9% | 1.9% | 1.3% | 1.2% | 1.2% | 1.0% | 0.9% | 0.5% | 0.6% | 0.6% | 0.5% | 0.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.